Last updated: September 12, 2026
Acalabrutinib maleate, marketed by AstraZeneca as Calquence, is a second-generation Bruton's tyrosine kinase inhibitor used primarily in chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). Calquence sales increased from approximately $0.7 billion in 2020 to more than $2.3 billion in 2023, driven by expanded frontline use and migration from ibrutinib to more selective BTK inhibitors. The commercial outlook remains favorable, but competition from zanubrutinib, pirtobrutinib, fixed-duration venetoclax regimens, and future generic entry will pressure long-term growth.
What is acalabrutinib maleate and how is Calquence positioned?
Acalabrutinib maleate is the maleate salt of acalabrutinib, a covalent, irreversible BTK inhibitor. Calquence is available in 100 mg capsules and 100 mg tablets. The tablet formulation is important because it avoids some of the administration restrictions associated with the original capsule product, including acid-reducing-agent interactions.
Acalabrutinib binds covalently to BTK at cysteine 481. The drug is designed to inhibit B-cell receptor signaling while producing less off-target inhibition of kinases associated with atrial fibrillation, bleeding, and other adverse events than first-generation ibrutinib.
| Attribute |
Calquence |
| Active ingredient |
Acalabrutinib maleate |
| Brand owner |
AstraZeneca |
| Drug class |
Covalent BTK inhibitor |
| Main indications |
CLL and SLL; MCL indication previously authorized in the U.S. |
| Dosage forms |
100 mg capsule; 100 mg tablet |
| Standard adult dose |
100 mg twice daily |
| Primary commercial markets |
United States, Europe, Japan, China, and other international markets |
| Main competitors |
Imbruvica, Brukinsa, Jaypirca, Venclexta-based regimens |
The U.S. Food and Drug Administration approved Calquence for adults with CLL or SLL in November 2019 and expanded the label in January 2021 to include previously untreated patients. FDA also granted accelerated approval for adult patients with mantle cell lymphoma (MCL) after at least one prior therapy in 2017. AstraZeneca later withdrew the U.S. MCL indication in 2023 after the required confirmatory study could not be completed as planned. The withdrawal was not based on a new safety signal. [1, 2]
What has been the financial trajectory for Calquence?
Calquence has developed into one of AstraZeneca’s largest hematology products. Reported product sales rose sharply as the drug moved into earlier-line CLL treatment.
| Fiscal year |
Approximate Calquence sales |
Commercial development |
| 2020 |
$0.7 billion |
Early CLL and MCL commercialization |
| 2021 |
$1.2 billion |
Broader CLL adoption and frontline use |
| 2022 |
$2.0 billion |
Continued replacement of ibrutinib in CLL |
| 2023 |
$2.3 billion |
Expansion in major markets and increased physician adoption |
AstraZeneca reported Calquence product sales of approximately $2.3 billion in 2023, with continued growth in the United States and international markets. The product’s trajectory has been stronger than the company’s initial commercial base because CLL treatment is shifting toward targeted oral agents and away from chemoimmunotherapy. [3]
Calquence sales are strategically important for AstraZeneca because the product helps offset eventual erosion of older oncology products and provides exposure to the large, chronic-treatment CLL market. Revenue is generated through repeated monthly prescriptions rather than one-time treatment courses. That creates a durable revenue stream, although it also increases sensitivity to payer formulary decisions and treatment sequencing.
What revenue risks could affect Calquence?
The main financial risks are:
- BTK class competition. Zanubrutinib has increasingly competed on efficacy data, particularly in relapsed CLL and other B-cell malignancies.
- Treatment-duration changes. Fixed-duration regimens using venetoclax can reduce cumulative exposure to continuous BTK therapy.
- Price pressure. Payers may use competing BTK inhibitors to negotiate discounts.
- U.S. patent erosion. A successful ANDA challenge could materially reduce U.S. revenue after patent expiry.
- Clinical differentiation. Physicians may favor pirtobrutinib after covalent BTK inhibitor failure because of its noncovalent binding mechanism.
- Indication concentration. CLL and SLL account for the principal commercial value after the U.S. MCL withdrawal.
How does Calquence compare with Imbruvica, Brukinsa, and Jaypirca?
Calquence competes in a market that is moving from first-generation ibrutinib toward more selective or next-generation BTK inhibitors.
| Product |
Active ingredient |
Company |
Binding type |
Key competitive position |
| Calquence |
Acalabrutinib |
AstraZeneca |
Covalent, irreversible |
Selective BTK inhibition; established CLL franchise |
| Imbruvica |
Ibrutinib |
AbbVie and Johnson & Johnson |
Covalent, irreversible |
First major BTK entrant; broader historical use |
| Brukinsa |
Zanubrutinib |
BeiGene |
Covalent, irreversible |
Strong efficacy and increasing share in B-cell malignancies |
| Jaypirca |
Pirtobrutinib |
Eli Lilly |
Noncovalent, reversible |
Designed for patients with prior covalent BTK inhibitor exposure |
| Venclexta combinations |
Venetoclax |
AbbVie and Roche |
BCL-2 inhibitor |
Fixed-duration and combination treatment alternative |
How does acalabrutinib compare with ibrutinib?
Acalabrutinib was developed to retain BTK activity while reducing some off-target effects associated with ibrutinib. Head-to-head data from the ELEVATE-RR study showed noninferior progression-free survival in previously treated high-risk CLL, with lower rates of atrial fibrillation and some cardiovascular events for acalabrutinib. [4]
That safety distinction has supported switching from ibrutinib to Calquence, especially in older patients and those with cardiovascular risk. The advantage is not absolute. Acalabrutinib can still cause hemorrhage, infections, cytopenias, atrial fibrillation, and other serious adverse reactions.
How does acalabrutinib compare with zanubrutinib?
Zanubrutinib has become the most direct threat to Calquence. It is also a second-generation covalent BTK inhibitor and has produced strong comparative results in CLL and other B-cell malignancies. Brukinsa’s commercial growth has been rapid, particularly in the United States and China.
Calquence benefits from an established installed base, broad regulatory approvals, and AstraZeneca’s hematology infrastructure. Brukinsa benefits from aggressive commercial expansion and data supporting high BTK occupancy. The competitive balance will depend on overall survival, atrial fibrillation rates, treatment persistence, pricing, and payer contracting.
What is the FDA regulatory status of acalabrutinib maleate?
The FDA-approved Calquence label covers CLL and SLL. The drug is administered at 100 mg approximately every 12 hours until disease progression or unacceptable toxicity.
The U.S. regulatory history includes:
| Date |
FDA event |
| October 2017 |
Accelerated approval for adult MCL after at least one prior therapy |
| November 2019 |
Approval for adult CLL or SLL |
| January 2021 |
Approval for previously untreated adult CLL or SLL |
| October 2023 |
Withdrawal of the U.S. MCL indication |
The MCL withdrawal reduces the U.S. label scope but does not remove Calquence’s principal commercial indication. CLL and SLL remain the core revenue markets. The withdrawal may also reduce the value of certain method-of-use claims directed specifically to MCL in the United States.
What patents protect acalabrutinib maleate and Calquence?
Calquence protection is based on several patent layers:
- Composition-of-matter protection for acalabrutinib and related chemical compounds.
- Salt and crystalline-form protection.
- Pharmaceutical-composition and tablet-formulation claims.
- Method-of-treatment claims for CLL, SLL, and other B-cell malignancies.
- Manufacturing and process patents.
- Pediatric-exclusivity or regulatory extensions where applicable.
The core U.S. acalabrutinib patent estate has been publicly associated with AstraZeneca and Acerta Pharma, the company AstraZeneca acquired in 2016. Public patent records identify U.S. Patent No. 9,624,278 among the patents associated with acalabrutinib. The compound patent has been reported with an expiration date in 2034, subject to patent-term adjustment, patent-term extension, and the scope of any Orange Book-listed claims.
Because patent listings and expiry calculations can change through terminal disclaimers, patent-term adjustments, pediatric extensions, and litigation outcomes, the controlling record is the FDA Orange Book and the USPTO Patent Center. [5, 6]
What formulations are protected?
The formulation estate is commercially important because Calquence has both capsule and tablet products. The tablet formulation may provide differentiated protection from the original capsule product, particularly where claims cover:
- Acalabrutinib maleate in a specific solid form.
- Excipients and dosage-unit composition.
- Immediate-release oral tablets.
- Dissolution characteristics.
- Stability and manufacturing processes.
- Administration with acid-reducing agents.
Formulation patents can delay a simple generic substitution even if a compound patent is challenged. They may not prevent every alternative formulation, however. A generic applicant can attempt to design around nonessential excipient, process, or dosage-form limitations while challenging the underlying compound or method claims.
When does acalabrutinib lose exclusivity?
The commercial loss-of-exclusivity date depends on which patents survive and whether an ANDA applicant prevails. A single headline expiry date is therefore inadequate.
The practical exclusivity sequence is likely to include:
- FDA regulatory exclusivity and any pediatric protection.
- Core compound patent expiry in the mid-2030s.
- Later-expiring formulation, salt, crystal-form, or method patents.
- Litigation settlements that could permit an agreed generic launch before the latest listed patent expiry.
- At-risk launch if a generic applicant wins or launches before final judgment.
Acalabrutinib’s principal U.S. generic risk is unlikely to be immediate. The more material risk is a patent challenge that narrows the effective protection period before the final listed patent expiry. The product’s chronic dosing and high annual treatment cost make it an attractive target for ANDA filers once the relevant patents are listed and challengeable.
Which companies are challenging Calquence patents?
No broad, definitive public record establishes a current market-wide generic challenge list for Calquence. ANDA litigation can develop through confidential Paragraph IV notices before a complaint becomes publicly visible, and an applicant may challenge one patent while carving out another.
A Paragraph IV certification would assert that a listed patent is invalid, unenforceable, or not infringed. AstraZeneca could file suit within 45 days of receiving notice, triggering a statutory stay of FDA approval for up to 30 months, subject to court action and statutory exceptions. [7]
The key commercial variables are:
- Whether the challenger targets the compound patent or only formulation patents.
- Whether the generic seeks approval for capsules, tablets, or both.
- Whether the method-of-use claims can be carved out of the label.
- Whether AstraZeneca settles and grants a licensed entry date.
- Whether the challenger launches at risk.
- Whether multiple filers create first-filer competition.
What is the Orange Book status of Calquence?
Calquence is an FDA-approved small-molecule drug, so its relevant patents are listed in the Orange Book rather than in the Purple Book. The Orange Book can identify patents associated with approved dosage forms and uses, but it does not provide a complete picture of every patent that may affect commercial launch.
Important distinctions include:
- Orange Book-listed patents may cover the approved product, formulation, or method of use.
- Manufacturing patents may not be listed.
- A patent can affect launch without being listed if the generic applicant must address it through another regulatory or litigation pathway.
- A use-code statement can limit the scope of a Paragraph IV dispute.
- Patent expiry dates do not automatically establish the first lawful generic launch date.
Calquence should therefore be assessed through the combined Orange Book, FDA label, USPTO records, court docket, and any publicly disclosed settlement agreement.
Is there biosimilar risk for acalabrutinib maleate?
There is no conventional biosimilar risk for acalabrutinib maleate because Calquence is a chemically synthesized small molecule, not a biologic. The relevant threat is an ANDA generic, not a 351(k) biosimilar.
Generic applicants must demonstrate pharmaceutical equivalence and bioequivalence. They may seek approval for the capsule, tablet, or both. The commercial impact could be substantial because generic substitution would affect pharmacy dispensing, payer reimbursement, and AstraZeneca’s net price.
The presence of two dosage forms creates both protection and risk. Separate formulation claims may delay generic tablet entry, while a successful capsule generic could still pressure overall brand pricing if the capsule remains clinically substitutable for a material patient segment.
What manufacturing and intellectual-property barriers affect generic entry?
Manufacturing barriers may include:
- Control of the maleate salt and solid-state form.
- Impurity specifications.
- Particle-size and dissolution control.
- Reproducible tablet compression.
- Stability under long-term storage.
- Commercial-scale synthesis of advanced intermediates.
- Compliance with oncology-product manufacturing standards.
These barriers are meaningful but generally less durable than a valid composition-of-matter patent. A well-capitalized generic company can often reproduce a small-molecule manufacturing process or develop a noninfringing route. The strongest protection remains a valid patent claim that covers the active ingredient, a required formulation feature, or an unavoidable treatment method.
What licensing deals and corporate transactions affect Calquence?
AstraZeneca acquired Acerta Pharma in 2016 in a transaction valued at up to approximately $7 billion, including an initial payment and contingent consideration. The transaction gave AstraZeneca control of acalabrutinib, then in development as ACP-196. [8]
The deal shaped Calquence’s commercial position by placing the product inside AstraZeneca’s global oncology portfolio, which includes hematology sales, regulatory operations, clinical development, and market access capabilities. No major third-party licensing arrangement is required to explain the product’s current commercial ownership. AstraZeneca is the controlling commercial and development organization.
What generic launch scenarios exist for Calquence?
Scenario one: delayed entry after core patent expiry
AstraZeneca retains substantial revenue through the mid-2030s, with gradual erosion from competitive products but no early generic shock. This is the strongest scenario for preserving brand economics.
Scenario two: settlement with an authorized or licensed generic
AstraZeneca permits entry before the latest patent expiry in exchange for a defined launch date, potentially with restrictions on formulation, indication, or launch volume. This can reduce litigation risk while preserving part of the remaining value.
Scenario three: successful Paragraph IV challenge
A generic applicant invalidates or avoids the key patent. Multiple generic entrants then reduce price and market share rapidly, particularly in the United States.
Scenario four: at-risk launch
A generic launches before final judgment. AstraZeneca may seek damages and injunctive relief. This scenario creates the highest short-term volatility for both companies and can accelerate payer conversion if the generic remains on the market.
How strong is the Calquence patent estate?
The estate appears commercially meaningful because it combines a long-lived compound patent position with formulation and method-of-use protection. Its strength is moderated by the predictable vulnerabilities of oral oncology products:
- Composition patents face validity and obviousness challenges.
- Method-of-use claims may be narrowed through label carve-outs.
- Formulation patents can be designed around.
- MCL-specific claims have less commercial value after the U.S. withdrawal.
- A successful first Paragraph IV filer can compress the effective exclusivity period.
The estate is stronger than a product protected only by late-stage method patents, but the financial outcome depends on the enforceability of the core compound claims and the precise Orange Book listing profile.
How should investors assess Calquence’s market outlook?
Calquence remains a growth-stage hematology franchise rather than a mature post-exclusivity product. The near-term outlook depends on continued CLL adoption and the product’s ability to retain share against Brukinsa.
The most important indicators are:
- Quarterly prescription growth in first-line CLL.
- Net price and gross-to-net discounting.
- Share migration from ibrutinib.
- Brukinsa comparative data and payer access.
- Uptake of Calquence tablets.
- Duration of therapy and fixed-duration regimen penetration.
- Public Paragraph IV notices and ANDA litigation.
- New patent listings or court decisions.
- AstraZeneca’s reported oncology revenue by region.
Calquence should generate substantial revenue before generic erosion becomes the central issue. The product’s risk profile is therefore asymmetric: competitive pressure is immediate and incremental, while generic risk is later but potentially abrupt.
Key Takeaways
- Acalabrutinib maleate is the active pharmaceutical ingredient in AstraZeneca’s Calquence.
- Calquence sales grew to approximately $2.3 billion in 2023 from roughly $0.7 billion in 2020.
- CLL and SLL are the core commercial indications after AstraZeneca withdrew the U.S. MCL indication in 2023.
- The principal commercial threat is zanubrutinib, followed by pirtobrutinib and fixed-duration venetoclax regimens.
- Calquence faces generic rather than biosimilar risk.
- The core U.S. patent position has been publicly associated with expiry in the mid-2030s, while formulation and method patents may affect the effective launch date.
- A Paragraph IV challenge, settlement, or at-risk generic launch could materially alter the revenue trajectory.
- AstraZeneca’s acquisition of Acerta Pharma secured control of the product and its underlying intellectual property.
- The franchise remains commercially durable, but long-term growth will depend on competitive differentiation and patent enforcement.
FAQs
Is acalabrutinib maleate the same as Calquence?
Yes. Calquence contains acalabrutinib, supplied as the maleate salt. The brand is marketed by AstraZeneca.
Is Calquence a chemotherapy drug?
No. Calquence is an oral targeted therapy that inhibits BTK. It is classified as a small-molecule kinase inhibitor.
Can Calquence be substituted with Brukinsa?
No automatic substitution should be assumed. Both are BTK inhibitors, but they have different labels, clinical data, dosing instructions, and regulatory approvals.
Does Calquence have pediatric exclusivity?
Any pediatric exclusivity or patent-term adjustment must be assessed against the current FDA Orange Book and USPTO records. It should not be inferred solely from the base patent expiration date.
What would cause Calquence sales to decline before generic entry?
The most likely causes are loss of share to zanubrutinib, increased use of pirtobrutinib after covalent BTK inhibitor failure, greater adoption of fixed-duration venetoclax regimens, payer discounts, and declining treatment duration.
References
- U.S. Food and Drug Administration. (2023). Calquence (acalabrutinib) prescribing information. https://www.accessdata.fda.gov
- U.S. Food and Drug Administration. (2023). FDA announces withdrawal of accelerated approval for Calquence in mantle cell lymphoma. https://www.fda.gov
- AstraZeneca. (2024). Annual report and Form 20-F 2023. https://www.astrazeneca.com/investor-relations/annual-reports.html
- Byrd, J. C., et al. (2021). Acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukemia. Journal of Clinical Oncology, 39(31), 3441-3452.
- U.S. Patent and Trademark Office. (n.d.). Patent Center: U.S. Patent No. 9,624,278. https://patentcenter.uspto.gov
- U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/
- U.S. Food and Drug Administration. (n.d.). Hatch-Waxman amendments and abbreviated new drug applications. https://www.fda.gov
- AstraZeneca. (2016). AstraZeneca to acquire global rights to acalabrutinib through acquisition of Acerta Pharma. https://www.astrazeneca.com/media-centre/press-releases.html
